Oncolytic Virus Immunotherapy

• Rannpháirtithe: Marchini, Antonio (Eagarthóir), Ilkow, Carolina S. (Eagarthóir), Melcher, Alan (Eagarthóir)
• Formáid: Leictreonach Caibidil leabhair
• Teanga: Béarla
• Foilsithe / Cruthaithe: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Ábhair: Medicine; Clinical & internal medicine; oncolytic viruses; melanoma; immunotherapy; checkpoint inhibitors; combinatory therapy; reovirus; oncolytic virus; adenovirus; oncolytic; virotherapy; targeting; immunogenic cell death; αvβ6 integrin; oncolytic adenovirus; cancer immunotherapy; multi-stage; immunostimulatory; arming; HSV-1; clinical trials; newcastle disease virus; NDV; cancer; immune checkpoint inhibitor; PD-1; PD-L1; CTLA-4; type I interferon; herpes simplex virus; retargeted virus; tropism retargeting; tumor; checkpoint inhibitor; vaccination; antigen-agnostic vaccination; HER2; parvovirus; tumor microenvironment; combination therapy; glioblastoma; pancreatic cancer; colorectal cancer; measles virus; vector engineering; immune checkpoint blockade; antitumor immune response; delivery; genetic modification; biomarkers; personalized oncolyticvirotherapy; class I HLA; immunosurveillance; immunoediting; oncogenic signaling; RAS; DNA methyltransferase inhibitor (DNMTi); viral mimicry; epigenetic silencing; adoptive T cell therapy; CAR T cell; pancreatic ductal adenocarcinoma; vesicular stomatitis virus; small molecule; cancer immune therapy; cancer therapy; n/a
• Rochtain ar líne: DOAB: download the publication; DOAB: description of the publication

Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. Thi...